Alpelisib clinical trials
Also written BYL719, Piqray and VIJOICE.
ClinicalTrials.gov finds 128 studies for Alpelisib. How that becomes 85 here
Every study that search finds has been read, to see whether and how it gives Alpelisib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 128Found by its intervention search · See all 128 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 109 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −5
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor MalignanciesNCT05627960 · Advice on earlier treatment; not given in this studyReport a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · Tersolisib, a different PI3K-alpha inhibitorReport a problem
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsNCT06993844 · Not given; a new PI3K-alpha drug is testedReport a problem
- Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and ChemotherapyNCT07573696 · Written for alectinib; alpelisib is not givenReport a problem
- EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)NCT07646171 · Earlier treatment; everolimus after it is studiedReport a problem
- 123Give Alpelisib to participants
- −16Observe patients on it, or give it outside a trial
- −3Compare another treatment with it
- −19Give it beside what is tested
- 85Test it: the count on this site
Get an email when these change. Save the Alpelisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 May 2019 · PIQRAY · NDA 212526 (FDA, Drugs@FDA)
- European Union
- 27 Jul 2020 · Piqray · EMEA/H/C/004804 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
85 studies that test it; most in 2014 (11)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 11 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 10 |
| 2022 | 9 |
| 2023 | 7 |
| 2024 | 6 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 47
Novartis Pharmaceuticals (34) · Columbia University (4) · Memorial Sloan Kettering Cancer Center (3) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (2) · UNICANCER (2) · Pamela Munster (2) · Assistance Publique Hopitaux De Marseille (1)
Often tested with
Tested in the same studies.
Olaparib (6) · Ribociclib (4) · Trametinib (3) · Fulvestrant (3) · Letrozole (3) · Buparlisib (3) · Binimetinib (3) · Paclitaxel (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Alpelisib is the comparator. A study of two new drugs counts under both.
- 1Gedatolisib · Celcuity Inc
- 1Inavolisib · Hoffmann-La Roche · next primary completion Nov 2026
New treatments tested with it · 4 most studied
New when their studies opened, with Alpelisib beside them; studies of each.
- 1Atirmociclib
- 1Imlunestrant
- 1Amcenestrant
- 1LSZ102
Reaching primary completion within a year · 13, 2 in phase 3
Studies that test Alpelisib, phase 3 first.
- Jan 2027Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Phase 3 · Novartis Pharmaceuticals
- Feb 2027Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationPhase 3 · Novartis Pharmaceuticals
- Dec 2026Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)Phase 2 · The Methodist Hospital Research Institute
- Dec 2026Human Models of Selective Insulin Resistance: Alpelisib, Part IPhase 1 · Columbia University
- Dec 2026Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPhase 2 · Tianjin Medical University Second Hospital
- Jan 2027A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsPhase 2 · Murdoch Childrens Research Institute
- Jan 2027Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerPhase 2 · Novartis Pharmaceuticals
- Feb 2027Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerPhase 1/2 · Novartis Pharmaceuticals
- Feb 2027Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerPhase 2 · Novartis Pharmaceuticals
- Mar 2027Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)Phase 2 · Centre Hospitalier Universitaire Dijon
Studies
Open first, then newest update. How each study uses Alpelisib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 85
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377One matched combination in ComboMATCHWritten as AlpelisibReport a problem
- EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)RecruitingPhase 2Novartis PharmaceuticalsNCT06997588In PIK3CA-related overgrowth (EPIK-P4)Written as AlpelisibReport a problem
- 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsRecruitingPhase 2Children's Hospital of PhiladelphiaNCT07543822In TIE2/PIK3CA vascular anomaliesWritten as alpelisib (BYL719)Report a problem
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.RecruitingPhase 2/3Novartis PharmaceuticalsNCT05948943Against placebo in PIK3CA lymphatic malformationsWritten as AlpelisibReport a problem
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06545682With pembrolizumab in breast cancer or melanomaWritten as Alpelisib + PembrolizumabReport a problem
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07679269Continued in a roll-over studyWritten as AlpelisibReport a problem
- Alpelisib Challenge Test (ACT)RecruitingPhase 1Columbia UniversityNCT07778524Single dose as an insulin challenge testWritten as Alpelisib 300 mgReport a problem
- Human Models of Selective Insulin Resistance: Alpelisib, Part IRecruitingPhase 1Columbia UniversityNCT06354088Its effect on insulin resistance in healthy volunteersWritten as Alpelisib 300 mgReport a problem
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)RecruitingPhase 2The Methodist Hospital Research InstituteNCT05660083With an iNOS inhibitor and nab-paclitaxel in metaplastic breast cancerReport a problem
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingPhase 2Murdoch Childrens Research InstituteNCT05983159In vascular malformations, beside mirdametinibWritten as AlpelisibReport a problem
- Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)RecruitingPhase 2Centre Hospitalier Universitaire DijonNCT05577754Against placebo in PIK3CA-related overgrowthWritten as Alpelisib (BYL719)Report a problem
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT05933395One gene-matched drug with fulvestrant after CDK4/6Written as AlpelisibReport a problem
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingPhase 2Tianjin Medical University Second HospitalNCT06739395One of many drugs matched to tumour geneticsReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label in one arm of a precision medicine trialReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour profileWritten as AlpelisibReport a problem
- Combination of Alpelisib and Trametinib in Progressive Refractory MeningiomasActive, not recruitingPhase 1Assistance Publique Hopitaux De MarseilleNCT03631953With trametinib in meningiomasWritten as AlpelisibReport a problem
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedPhase 3Novartis PharmaceuticalsNCT04729387With olaparib against chemotherapy in ovarian cancer (EPIK-O)Written as AlpelisibReport a problem
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedPhase 3Spanish Breast Cancer Research GroupNCT05063786With trastuzumab, against chemotherapy (ALPHABET)Written as AlpelisibReport a problem
- Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT04980833Long-term use in PIK3CA-related overgrowthWritten as AlpelisibReport a problem
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedPhase 2UNICANCERNCT05625087Switch to it against ribociclib on ctDNA (SAFIR03-ARRIBA)Written as AlpelisibReport a problem
See all 85 studies that test Alpelisib →
Behind its US label · 2 — the studies the FDA label of PIQRAY, VIJOICE describes
From the Clinical Studies section of PIQRAY (2025-12), VIJOICE (2025-11), as openFDA has it. A study the site does not hold is left out.
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.CompletedPhase 3Novartis PharmaceuticalsNCT02437318Report a problem
- Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received AlpelisibCompletedNovartis PharmaceuticalsNCT04285723Report a problem
Tested on its own · 16 — no other medicine in its arm
- EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)RecruitingPhase 2Novartis PharmaceuticalsNCT06997588In PIK3CA-related overgrowth (EPIK-P4)Written as AlpelisibReport a problem
- 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsRecruitingPhase 2Children's Hospital of PhiladelphiaNCT07543822In TIE2/PIK3CA vascular anomaliesWritten as alpelisib (BYL719)Report a problem
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.RecruitingPhase 2/3Novartis PharmaceuticalsNCT05948943Against placebo in PIK3CA lymphatic malformationsWritten as AlpelisibReport a problem
- Alpelisib Challenge Test (ACT)RecruitingPhase 1Columbia UniversityNCT07778524Single dose as an insulin challenge testWritten as Alpelisib 300 mgReport a problem
- Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)RecruitingPhase 2Centre Hospitalier Universitaire DijonNCT05577754Against placebo in PIK3CA-related overgrowthWritten as Alpelisib (BYL719)Report a problem
- Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)Active, not recruitingPhase 2Novartis PharmaceuticalsNCT04980833Long-term use in PIK3CA-related overgrowthWritten as AlpelisibReport a problem
- Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedPhase 2UNICANCERNCT05625087Switch to it against ribociclib on ctDNA (SAFIR03-ARRIBA)Written as AlpelisibReport a problem
- Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04589650Against placebo in PIK3CA-related overgrowth (EPIK-P2)Written as AlpelisibReport a problem
- A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719CompletedNot applicableLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT03138070Short course before surgery in head and neck cancerWritten as BYL719Report a problem
- Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal CancerTerminatedPhase 2University of ArizonaNCT03601507Before surgery in HPV-associated oropharyngeal cancerWritten as AlpelisibReport a problem
- SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast CancerTerminatedPhase 2UNICANCERNCT03386162With fulvestrant as maintenance against chemotherapy (SAFIR-PI3K)Written as AlpelisibReport a problem
- Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast CancerCompletedPhase 2Peter MacCallum Cancer Centre, AustraliaNCT02506556Alone in advanced breast cancerWritten as BYl719Report a problem
- Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.CompletedPhase 1Novartis PharmaceuticalsNCT02624557Single dose across liver impairmentWritten as AlpelisibReport a problem
- A Study of BYL719 in Adult Patients With Advanced Solid MalignanciesCompletedPhase 1Novartis PharmaceuticalsNCT01387321First study in Japanese patientsWritten as BYL719Report a problem
- A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneCompletedPhase 1Novartis PharmaceuticalsNCT01219699First-in-human, alone and with fulvestrant in one armWritten as BYL719Report a problem
- An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.Status unknownPhase 2Yonsei UniversityNCT02145312Alone in head and neck cancerWritten as BYL719Report a problem
Tested with established drugs · 25 — they are given beside it
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07679269Continued in a roll-over studyWritten as AlpelisibReport a problem
- Human Models of Selective Insulin Resistance: Alpelisib, Part IRecruitingPhase 1Columbia UniversityNCT06354088Its effect on insulin resistance in healthy volunteersWritten as Alpelisib 300 mgReport a problem
- Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT05038735Added to fulvestrant against placeboWritten as AlpelisibReport a problem
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04544189Added to fulvestrant against placeboWritten as AlpelisibReport a problem
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04524000With fulvestrant in Japanese patientsWritten as AlpelisibReport a problem
- Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04208178Added to trastuzumab and pertuzumab maintenance (EPIK-B2)Written as AlpelisibReport a problem
- Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN LossTerminatedPhase 3Novartis PharmaceuticalsNCT04251533Added to nab-paclitaxel in triple-negative breast cancer (EPIK-B3)Written as alpelisibReport a problem
- Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine TreatmentCompletedPhase 4Novartis PharmaceuticalsNCT05631795With fulvestrant, a phase 4 safety studyWritten as AlpelisibReport a problem
- Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast CancerActive, not recruitingPhase 2Marina N SharifiNCT04762979Added to continued endocrine therapy after progressionWritten as AlpelisibReport a problem
- Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.CompletedPhase 3Novartis PharmaceuticalsNCT02437318On the US labelAdded to fulvestrant (SOLAR-1)Written as AlpelisibReport a problem
- BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT01870505Added to letrozole or exemestane, dose findingWritten as BYL719Report a problem
- Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantTerminatedPhase 2Novartis PharmaceuticalsNCT04862143With fulvestrant in a decentralised trialWritten as AlpelisibReport a problem
- Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnPhase 2National Cancer Institute (NCI)NCT05967286Added to olaparib in metastatic breast cancer (ComboMATCH)Written as AlpelisibReport a problem
- Effect of Alpelisib in Healthy VolunteersCompletedPhase 1Columbia UniversityNCT05733455Its effect on insulin in healthy volunteersWritten as Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)Report a problem
- Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast CancerCompletedPhase 1UNC Lineberger Comprehensive Cancer CenterNCT01300962With capecitabine, beside a buparlisib armWritten as BYL719Report a problem
- BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast CancerCompletedPhase 1/2Priyanka SharmaNCT02379247Added to nab-paclitaxel in breast cancerWritten as BYL-719 (alpelisib)Report a problem
- Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)CompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02282371Added to cetuximab and radiation in head and neck cancerWritten as BYL719Report a problem
- Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck CancerCompletedPhase 1University Health Network, TorontoNCT02537223Added to cisplatin and radiotherapyWritten as BYL719Report a problem
- BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic CancerCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT02155088Added to gemcitabine and nab-paclitaxel in pancreatic cancerWritten as BYL719Report a problem
- BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group StudyTerminatedPhase 1howard safranNCT02550743Added to capecitabine and radiation in rectal cancerWritten as BYL719Report a problem
Showing 20 of 25. See all 25 →
Tested in a combination · 44 — another drug in the study is under test too
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377One matched combination in ComboMATCHWritten as AlpelisibReport a problem
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06545682With pembrolizumab in breast cancer or melanomaWritten as Alpelisib + PembrolizumabReport a problem
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)RecruitingPhase 2The Methodist Hospital Research InstituteNCT05660083With an iNOS inhibitor and nab-paclitaxel in metaplastic breast cancerReport a problem
- A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular MalformationsRecruitingPhase 2Murdoch Childrens Research InstituteNCT05983159In vascular malformations, beside mirdametinibWritten as AlpelisibReport a problem
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT05933395One gene-matched drug with fulvestrant after CDK4/6Written as AlpelisibReport a problem
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingPhase 2Tianjin Medical University Second HospitalNCT06739395One of many drugs matched to tumour geneticsReport a problem
- Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingPhase 2Oslo University HospitalNCT04817956Off-label in one arm of a precision medicine trialReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One of many approved drugs matched to tumour profileWritten as AlpelisibReport a problem
- Combination of Alpelisib and Trametinib in Progressive Refractory MeningiomasActive, not recruitingPhase 1Assistance Publique Hopitaux De MarseilleNCT03631953With trametinib in meningiomasWritten as AlpelisibReport a problem
- Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation DetectedTerminatedPhase 3Novartis PharmaceuticalsNCT04729387With olaparib against chemotherapy in ovarian cancer (EPIK-O)Written as AlpelisibReport a problem
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedPhase 3Spanish Breast Cancer Research GroupNCT05063786With trastuzumab, against chemotherapy (ALPHABET)Written as AlpelisibReport a problem
- Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT01872260With ribociclib and letrozole, both before approvalWritten as BYL719Report a problem
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)CompletedPhase 1/2Kura Oncology, Inc.NCT04997902With tipifarnib in head and neck cancerWritten as AlpelisibReport a problem
- BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast CancerCompletedPhase 1Vanderbilt-Ingram Cancer CenterNCT01791478Added to letrozole, dose findingReport a problem
- A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive, not recruitingPhase 2GOG FoundationNCT05154487With fulvestrant in endometrial cancerWritten as Alpelisib PillReport a problem
- Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedPhase 3Novartis PharmaceuticalsNCT03439046With fulvestrant second line, molecular features studiedWritten as AlpelisibReport a problem
- Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsTerminatedPhase 2M.D. Anderson Cancer CenterNCT04216472With nab-paclitaxel in triple-negative breast cancerWritten as AlpelisibReport a problem
- SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)Active, not recruitingPhase 2Borstkanker Onderzoek GroepNCT05392608With fulvestrant beyond progression on fulvestrant (SEQUEL-Breast)Written as Alpelisib 150 MG Oral Tablet [Piqray]Report a problem
- Alpelisib And Sacituzumab Govitecan For Treatment Of Breast CancerActive, not recruitingPhase 1University of Kansas Medical CenterNCT05143229With sacituzumab govitecan, dose findingWritten as AlpelisibReport a problem
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingPhase 1/2Criterium, Inc.NCT05230810With tucatinib in HER2-positive breast cancerWritten as AlpelisibReport a problem
Showing 20 of 44. See all 44 →
Beside a new treatment under test · 5 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Alpelisib: atirmociclib 1 · Imlunestrant 1 · amcenestrant 1 · LSZ102 1
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingPhase 1Olema Pharmaceuticals, Inc.NCT05508906Partner of new palazestrant in one armWritten as AlpelisibReport a problem
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT04188548Partner of new imlunestrant in one armWritten as AlpelisibReport a problem
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220Partner of new elacestrant in one armWritten as AlpelisibReport a problem
- Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerTerminatedPhase 1/2SanofiNCT03284957Partner of new amcenestrant in one armWritten as AlpelisibReport a problem
- Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast CancersTerminatedPhase 1Novartis PharmaceuticalsNCT02734615Partner of new LSZ102 in one armWritten as BYL719Report a problem
Beside supportive care · 8 — a supportive treatment or test is studied
- A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.RecruitingEarly Phase 1Rambam Health Care CampusNCT05753657Treatment while pioglitazone treats hyperinsulinaemiaReport a problem
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05090358In every armTreatment while diets or canagliflozin prevent its hyperglycaemiaWritten as AlpelisibReport a problem
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsCompletedPhase 2MedSIRNCT04300790In every armTreatment while metformin prevents its hyperglycaemiaWritten as AlpelisibReport a problem
- Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and FulvestrantTerminatedPhase 2Novartis PharmaceuticalsNCT04899349In every armTreatment while dapagliflozin prevents its hyperglycaemiaWritten as AlpelisibReport a problem
- A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast CancerTerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT05966584In every armTreatment while benralizumab prevents its rashWritten as fulvestrant or AIs) and PI3K inhibition (alpelisib)Report a problem
- Feasibility of Fasting & Exercise in Pts With HR+ MBCCompletedNot applicableDana-Farber Cancer InstituteNCT04708860Treatment while fasting and exercise are testedReport a problem
- Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast CancerStatus unknownNot applicableCentre Hospitalier Universitaire de BesanconNCT05107388Treatment while glucose monitoring is studiedReport a problem
- Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast CancerStatus unknownPhase 2Saint Luke's Health SystemNCT05025735Treatment while dapagliflozin is added against hyperglycaemiaReport a problem
One option of several · 6 — a test or a strategy chooses among drugs
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One molecular-typed option in salivary gland cancerWritten as alpelisib+fulvestrantReport a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingPhase 2University of MiamiNCT05826964One switch option guided by blood DNAWritten as PI3K inhibitor + SERDReport a problem
- Biology Guided Therapy for Breast Cancer for ER PositiveTerminatedPhase 2Inova Health Care ServicesNCT04965688One option in biopsy-guided therapy selectionReport a problem
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnEarly Phase 1OHSU Knight Cancer InstituteNCT05238831In every armOne option in adaptive precision treatment (SMMART)Written as AlpelisibReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One option in tailored therapy (ROME)Written as AlpelisibReport a problem
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNot applicablePeter MacCallum Cancer Centre, AustraliaNCT04801966In every armOne option in individually tailored treatmentWritten as AlpelisibReport a problem
As the comparator · 3 — what is tested is compared with Alpelisib
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862Comparator for new inavolisib, both with fulvestrant (INAVO121)Written as AlpelisibReport a problem
- Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingPhase 2Yonsei UniversityNCT06837792One comparator option against trastuzumab deruxtecanReport a problem
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingPhase 3Celcuity IncNCT05501886Comparator with fulvestrant in PIK3CA-mutant disease (VIKTORIA-1)Written as AlpelisibReport a problem
Observed · 16 — patients on it are followed, or it is given outside a trial
- A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesNot yet recruitingNovartis PharmaceuticalsNCT07767877One inhibitor observed in vascular anomaliesReport a problem
- A Post Marketing Surveillance on Piqray in KoreaRecruitingNovartis PharmaceuticalsNCT05293470Post-marketing surveillance in KoreaReport a problem
- Managed Access Programs for BYL719, AlpelisibAvailableNovartis PharmaceuticalsNCT04085653Managed access programmesWritten as alpelisibReport a problem
- A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaCompletedNovartis PharmaceuticalsNCT04943497One treatment observed in routine practiceReport a problem
- Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating AlpelisibCompletedHealthPartners InstituteNCT06083038Glucose monitoring after starting it, observedWritten as AlpelisibReport a problem
- Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-worldCompletedNovartis PharmaceuticalsNCT05022342Outcomes by PIK3CA mutation in practiceReport a problem
- A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world SettingTerminatedNovartis PharmaceuticalsNCT04967248Post-authorisation safety with fulvestrant, observedReport a problem
- Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational StudyCompletedNovartis PharmaceuticalsNCT05294289Quality of life in PROS, observedReport a problem
- Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using AlpelisibCompletedNovartis PharmaceuticalsNCT05073120Clinicians surveyed on its hyperglycaemiaReport a problem
- A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibCompletedNovartisNCT06705504Effectiveness and safety in Europe, observedReport a problem
- Compassionate Use of BYL 719 AlpelisibNo longer availableNew Mexico Cancer Research AllianceNCT03941782Compassionate useWritten as AlpelisibReport a problem
- Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast CancerCompletedNovartis PharmaceuticalsNCT05982886Treatment patterns after PIK3CA testing, observedReport a problem
- A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of TherapyCompletedNovartis PharmaceuticalsNCT05853432With fulvestrant after earlier fulvestrant, observedReport a problem
- Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received AlpelisibCompletedNovartis PharmaceuticalsNCT04285723On the US labelChart review after compassionate use in PROS (EPIK-P1)Report a problem
- Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast CancerNo longer availableNovartis PharmaceuticalsNCT03706573Managed access in advanced breast cancerWritten as alpelisibReport a problem
- Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownBlokhin's Russian Cancer Research CenterNCT04852081Among treatments, therapy sequences in MoscowWritten as AlpelisibReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAsOct 19, 2026NCT07543822
Codes
What other systems call Alpelisib · ClinicalTrials.gg INT006407
- MeSH (NLM) C585539AlpelisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 08W5N2C97QALPELISIBConfirmed FDA, NLM, Wikidata
- RxNorm 2169285Confirmed FDA, Wikidata
- Wikidata Q27074391alpelisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C94214AlpelisibOne source FDA
- DrugBank DB12015One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585539 | Alpelisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 08W5N2C97Q | ALPELISIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2169285 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27074391 | alpelisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C94214 | Alpelisib | One source FDA |
| DrugBank | DB12015 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.